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INTRODUCTION
Clostridium difficile (C. difficile) is the predominant causative
agent of the nosocomial and antibiotic-associated diarrhea
(1). The clinical presentation of C. difficile-associated disease
(CDAD) varies from asymptomatic colonization to mild diar-
rhea to severe life-threatening pseudomembranous colitis
(PMC) (1-4). Fulminant colitis develops in approximately 1
to 3% of the patients, leading to ileus, toxic megacolon, per-
foration, and death (1). PMC is known to develop after the
antibiotic administration, whereas the antituberculosis agents
are rarely associated with this disorder (1, 5).
In recent years, a high-leveled toxin-producing strain of
C. difficile polymerase chain reaction (PCR) ribotype 027 has
been isolated in North America, Europe (4), and Japan (6),
which were associated with a more severe course, higher mor-
tality, increased risk of relapse, and complication. This in-
creased virulence is presumably associated with higher lev-
els of toxin production in C. difficile PCR ribotype 027 strains
(3, 4). This mechanism involves a partial deletion in the tcdD
gene encoding a down-regulator of the expression of toxins
A and B, as well as the production of a binary toxin, whose
role in the pathogenesis is yet unknown (3, 4). We report the
first isolation case of C. difficile PCR ribotype 027 from a pa-
tient with refractory and fulminant C. difficile PMC in Korea.
CASE REPORT
A 52-yr-old woman, taking oral vancomycin 125 mg daily
for recurrent PMC, was readmitted with high fever and recur-
rent watery diarrhea in late April 2008. She had been dis-
charged 22 days ago, after a prolonged stay in the intensive
care unit (ICU) with C. difficile PMC secondary to the septic
shock and acute renal failure.
She has had a traumatic paraplegia and neurogenic bladder
for several years. At first admission, she had been treated for
active pulmonary tuberculosis combined with pneumonia;
rifampin (600 mg/day), isoniazid (300 mg/day), ethambu-
tol (800 mg/day), pyrazinamide (1,500 mg/day), levofloxacin
(750 mg/day), amikacin (750 mg/day) and azithromycin (500
mg/day) since December 5, 2007. Until pneumonic consol-
idation had improved; levofloxacin, amikacin, and azithro-
mycin were used during 8, 5, and 3 days, respectively. She
developed C. difficile PMC with septic shock on day 13 of
anti-tuberculosis therapy, and then she had four document-
ed episodes of C. difficile PMC (Fig. 1). C. difficile toxin A/B
assay of the stool culture taken on admission day 3 gave posi-
tive result on C. difficile. On admission day 15, the sigmoi-
doscopic examination revealed scattered whitish to yellow-
ish pseudomembranes with edematous hyperemic mucosa
from the rectum to the descending colon (Fig. 2). Biopsy from
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The First Case of Antibiotic-associated Colitis by Clostridium difficile
PCR Ribotype 027 in Korea
Clostridium difficile (C. difficile) is a common causative agent of pseudomembranous
colitis (PMC). C. difficile-associated diarrhea (CDAD) ranges from mild diarrhea to
life threatening PMC. Recently, a highly virulent strain of C. difficile polymerase chain
reaction ribotype 027 was found in North America, Europe, and Japan. A 52-yr-old
woman with anti-tuberculosis medication and neurogenic bladder due to traffic acci-
dent experienced five episodes of C. difficile PMC after taking antibiotics for pneu-
monia along with septic shock and acute renal failure. She was readmitted to the
intensive care unit and treated with oral vancomycin with refractory of oral metron-
idazole, inotropics and probiotics for over 60 days. C. difficile isolated both at the
first and the last admission was identified as C. difficile ribotype 027 by ribotyping,
toxinotyping, and tcdC gene sequencing, which turned out the same pathogen as
the epidemic hypervirulent B1/NAP1 strain. This is the first case of C. difficile PCR
ribotype 027 in Korea. After discharge, she was maintained on probiotics and rifax-
imin for 3 weeks. She had no relapse for 6 months. 
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Accepted : 30 April 2009the sigmoid colon revealed acute and chronic inflammation
(Fig. 3). With a refractory of oral metronidazole for 8 days,
she was treated with oral vancomycin and became well after
4 weeks. In spite of the oral vancomycin maintenance thera-
py, she was repeatedly readmitted with C. difficile PMC and
required a stay in ICU due to the septic shock. 
On this admission, her blood pressure was 60/30 mmHg,
pulse rate 100/min, respiratory rate 20/min, and body tem-
perature elevated to 38.4℃. Her lip and tongue were severely
dehydrated, but her breathing sounds were normal on both
lung fields. Her abdomen was soft and obese with direct ten-
derness in the whole abdomen area, and her bowel sounds
were hyperactive. Laboratory data on admission were as fol-
lows: hemoglobin 10.0 g/dL, hematocrit 30.7%, white blood
cell count 1,700/μ L with 70.7% segmental neutrophil, pla-
telet 162,000/μ L, ESR 3 mm/hr, and CRP 32.29 mg/dL. Pro-
thrombin and partial thromboplastin times were slightly pro-
longed to 12.8 (76%) and 30.7 sec, respectively. Liver func-
tion test results were: total protein 4.8 g/dL, albumin 2.5 g/
dL, total bilirubin 0.4 mg/dL, direct bilirubin 0.2 mg/dL, ALT
12 IU/L, and AST 16 IU/L. Furthermore, BUN was 38 mg/
dL, creatinine 2.8 mg/dL, serum sodium 135 mEq/L, potas-
sium 5.2 mEq/L, chloride 100 mEq/L, and EtCO218 mEq/L.
Despite vigorous hydration and inotropics, the septic shock
was out of control. Intravenous immunoglobulin and mero-
penem were administered, and oral vancomycin (250 mg
four times daily), with suspicious recurrent of the 5th C. dif-
ficile PMC, was prescribed to the patient. Anti-tuberculosis
agents were discontinued due to an adequate course for 6
months. Diarrhea and fever was subsided after 5 days. 
Blood and urine cultures were negative; thus, meropenem
was discontinued. Stool specimens were anaerobically cultured
in each episode, and all isolates were identified as C. difficile
by Vitek ANI card (bioMerieux
�Sa, Marcy l’Etoile, France).
Stool specimens were positive for toxin A/B using VIDAS
C. difficile CDAB (bioMerieux
�Sa, Marcy l’Etoile, France).
We characterized the C. difficile strain isolated at both the
first and the last admissions. The Clinical and Laboratory
Standards Institute agar dilution test revealed that both iso-
lates were resistant to ampicillin (MIC=2 μ g/mL), cefoxitin
(MIC>128 μ g/mL), cefotetan (MIC=128 μ g/mL), clindamy-
cin (MIC>128 μ g/mL), imipenem (MIC=16 μ g/mL) and
moxifloxacin (MIC=16 μ g/mL), and sensitive to piperacillin
(MIC=16 μ g/mL), vancomycin (MIC=2 μ g/mL), and metron-
idazole (MIC=4 μ g/mL). 
PCR ribotyping was performed using the method desc-
ribed by Stubbs et al. (7). Briefly, DNA was extracted by boil-
ing bacteria suspension with 5% Chelex-100 (Sigma Co., St
Louis, MO, USA). The supernatant (10 μ L) of the DNA ex-
tract was added to a 40 μ L PCR mixture containing 1.5 U
of Taq polymerase (AmpliTaq Gold, Applied Biosystems,
Foster City, CA, USA), 0.4 mM dNTP, 4.0 mM MgCl2, 10
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Fig. 2. Sigmoidoscopic examination revealed scattered whitish to yellowish pseudomembrane with edematous hyperemic mucosa from
rectum to descending colon. (A) the first, (B) the second, (C) the third, and (D) the fourth admissions.
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Fig. 1. Clinical course of the patient. Changes
in serum CRP (gray line), diarrhea number
(black bars), and medication per day are
shown. HERZ, isoniazid 300 mg, ethambu-
tol 800 mg, rifampin 600 mg, pyrazinamide
1,500 mg; Levo/Pip+TZ/AMK, levofloxacin,
piperacillin, tazobatam, amikacin; IVIG, intra-
venous immunoglobulin; MDZ, metronida-
zole; Vanco, vancomycin; Adm, admission.522 C.H. Tae, S.-A. Jung, H.J. Song, et al.
mM Tris-HCl pH 8.30, 50 mM KCl (1X PCR Buffer II,
Applied Biosystems) and 20 ρ mol of each primer (5′ -CTGG-
GGTGAAGTCGTAACAAGG-3′ and 5′ -GCGCCCTTT-
GTAGCTTGACC-3′ ). Reaction mixtures were subjected to
40 cycles of denaturation at 95℃for 1 min, annealing at 55℃
for 1 min, and extension at 72℃ for 2 min and a last exten-
sion at 72℃ for 7min. A molecular size standard (100 bp;
Invitrogen, Carlsbad, CA, U.S.A.) was run with an electro-
phoresis of amplification products, and analyzed with Molec-
ular Analyst software (Bio-Rad Laboratory, Hercules, CA,
U.S.A.). PCR ribotyping revealed that both the first and the
last isolates were the same type as C. difficile ribotype 027
(Fig. 4A). Toxinotyping of C. difficile isolates was performed
by the method of Rupnik et al. (8). Restriction patterns of
this patient’s isolates by B1 and A3 PCRs revealed toxino-
type III (Fig. 4B). Sequencing of the tcdC gene of both the
first and the last isolates using the primer pairs (5′ -TCTCT-
ACAGCTATCCCTGGT-3′ and 5′ -AAAAATGAGGGTA-
ACGAATTT-3′ ) (9) showed both 18-bp deletions and a sin-
gle nucleotide deletion at position 117 (Fig. 5), identical to
the tcdC-sc1 genotyping classified by Curry et al. (10).
She was placed on the vancomycin-tapering schedule of
125 mg at 3-day intervals for over 60 days and ultimately
made a satisfactory recovery. The subsequent stool samples
on the day 17 were negative for C. difficile toxin and culture.
One day after completing the vancomycin treatment, she was
discharged without complications. After discharge, she was
maintained on probiotics and rifaximin for 3 weeks. She had
no relapse for 6 months.
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Fig. 5. Sequence of tcdC con-
taining both 18-bp deletions
(white arrows) and a single
nucleotide deletion at position
117 (black arrows). 
Reference strain 
(VPI10463)
Patient’s isolate
Fig. 3. A representative mucosal lesion with accompanying acute
and chronic inflammation. Classic pseudomembranes were not
present, but necroinflammatory exudates covered the mucosal
ulcerations (H&E stain, ×200). 
Fig. 4. PCR products and restriction patterns
of C. difficile ribotype 027 isolates from the
patient. (A) Identical PCR ribotype profiles
obtained from both the first and the last iso-
lates. Lanes: M, 100 bp DNA ladder; 1, the
last isolate; 2, the first isolate. (B) Types of
restriction patterns by B1 and A3 PCR show-
ing toxinotype III. Lanes: M, DNA size mark-
er; 1, 4, Acc I restriction patterns of B1 frag-
ment; 2, 5, HincII restriction patterns of B1
fragment; 3, 6, EcoRI restriction patterns of
A3 fragment.
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DISCUSSION
Since the first description of C. difficile by Hall and O’Toole
in 1935, C. difficile has been recognized as the causative agent
of the nosocomial diarrhea and the nearly exclusive cause of
PMC in 1978 (11). At present, C. difficile is the cause of ap-
proximately 25% of all cases of antibiotic-associated diarrhea
worldwide (12). The most common inducing agents have
been known to be clindamycin and the broad-spectrum ce-
phalosporin, but nearly all agents with an antibacterial spec-
trum may be responsible (1-4). On the other hand, anti-tuber-
culosis agents are rarely associated with this disorder (1, 5).
Among these agents, rifampin is postulated to be the cause
of PMC, because it has an antibiotic effect on a wide range
of bacteria, whereas isoniazid and ethambutoal had little or
no effect on the intestinal flora (13). In our case, the patient
had taken not only antibiotic agents such as levofloxacin,
amikacin, and azithromycin for several days, but also rifampin
for 6 months. The latter might be the reason why she suffered
from the recurrent fatal PMC five times for a long time.
The possible high risk factors for recurrent CDAD includ-
ed patients with chronic renal failure, previous multiple epi-
sodes of CDAD, continued therapy using other antibiotics,
community-acquired CDAD, high blood cell count (≥15
×109/L), and those infected with certain strains of C. difficile
(14, 15). Older age, a high leukocyte count, and renal failure
at the first recurrence were also strongly associated with the
complicated CDAD (16). In our case, major risk factors for
recurrent PMC were previous multiple episodes of CDAD,
long-term administration of anti-tuberculosis agent includ-
ing rifampin, and, most of all, the highly virulent C. difficile.
Recommendations for treatment of CDAD are supportive
care, withdrawal of the implicated antibiotics, and avoidance
of antiperistaltic drugs and the use of oral metronidazole or
oral vancomycin (1-3). Clinical resolution could be observed
in almost 90% of the patients treated by oral metronidazole
and vancomycin (2). Approximately 15% of the patients ex-
perienced relapse after initial therapy and required retreat-
ment, sometimes with an extended, tapering regimen for 4-
to 6-week period (1). 
Recently, the epidemiology of C. difficile appears to be
changing. Since 2002, outbreaks of severe CDAD associat-
ed with increased frequency and severity, as well as reduced
responses to the metronidazole treatment have turned the
attention onto a new strain (2, 6). The emergence of a new
strain has changed the risk group, prognosis, and treatment
strategies (3). This new strain is now known in North Amer-
ica as BI/NAP1 and in Europe as ribotype 027 (2, 17). It pro-
duces about 15 to 20 times the amount of toxins A and B
due to the deletion of tcdC gene, which, under normal con-
dition, negatively regulates the toxin production. Because
toxins A and B are the primary virulence factors of C. diffi-
cile (2), the increased virulence could be due to the increased
toxin production throughout the log phase of growth (4). In
Quebec outbreaks, the rate of nosocomial disease was at least
five times higher than the historical average (18). In addition,
mortality rates rose up to 13.8%, and incidence on individ-
uals aged 65 yr or more increased from 102 per 100,000 in
1991-1992 to 866 per 100,000 in 2003 (4). 
Currently, the standardized treatment for the highly viru-
lent C. difficile strain, which does not respond to oral metron-
idazole and vancomycin, is not available (19); thus colecto-
my is presently the considerable treatment choice (20). How-
ever, the mortality rate of this procedure ranges from 35 to
57% (3, 12). Various investigational trials, such as biothera-
py, probiotics, stool implants, vaccination, and tapering and
pulse-dosing of oral vancomycin, are being studied as poten-
tial treatments for severe CDAD (3, 12). Intravenous immu-
noglobulin may have beneficial effects on patients with refrac-
tory, recurrent or severe disease; however, no controlled data
are available (19). In the present case, pulse-dosing of oral
vancomycin, probiotics, and immunotherapy were used. 
At present, it is not easy for physicians to confirm this high-
ly virulent C. difficile strain. Because this strain is not univer-
sal, most laboratories are not equipped to perform PCR, which
requires technical expertise, on a routine basis (21, 22). We
suspected the presence of a highly virulent C. difficile strain,
and thus the sample was referred to a research laboratory for
detection the strain. PCR ribotyping appears to be the best
method for initial detection, being reproducible, quick and
easy to perform, and sufficiently discriminatory, it uses spe-
cific primers complementary to the 3′ end of the 16S rRNA
gene and to the 5′ end of the 23S rRNA gene to amplify the
variable-length intergenic spacer regions (23). Isolates from
the patient were identified as the hypervirulent C. difficile 027
by clinical manifestations and molecular typing. To the best
of our knowledge, this is the first case report of the C. difficile
PCR ribotype 027 strain in Korea. Considering the virulence
of this strain, it is important to be aware of the emergence of
C. difficile in Korea to prevent the spreading of this strain.
The emergence of C. difficile PCR ribotype 027 could be an
implication of outbreaks associated with severe CDAD. Pre-
vention is best accomplished by judicious use of antibiotics
and infection control programs (24). In addition, C. difficile
PCR ribotype 027 should be suspected, if there is an increase
of prevalence or severity of CDAD. Early treatment is criti-
cal to the outcome of the patient and may reduce spreading
of the organism by stopping diarrhea (25).
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